DR-461 Identifying biomarkers that predict outcomes in BRAFV600E mutant colorectal cancer

This project aims to understand how genetic alteration in an important cancer signalling pathway can impact treatment response and prognosis in patients with BRAFv600E mutant colorectal cancer (CRC). Using the available mutation data and RNA sequencing data, we will investigate genetic and transcriptional factors that influence outcomes. Insights from this research could identify important predictive biomarkers to improve the way we treat patients from this poor prognosis group. Supplementary laboratory experiments, including the use of patient-derived tumour organoid models, analysing tumor DNA from patient blood samples and spatial transcriptomics of tumour tissue, will further investigate findings. 

Frederic Hollande, The University of Melbourne, Australia